Compare DOYU & MXCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DOYU | MXCT |
|---|---|---|
| Founded | 2014 | 1999 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Programming Data Processing | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 134.3M | 136.2M |
| IPO Year | 2019 | 2021 |
| Metric | DOYU | MXCT |
|---|---|---|
| Price | $3.55 | $1.45 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 4 | 6 |
| Target Price | ★ $4.78 | $4.11 |
| AVG Volume (30 Days) | 28.8K | ★ 1.1M |
| Earning Date | 11-19-2026 | 11-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $33,026,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $15.53 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $3.43 | $0.64 |
| 52 Week High | $7.23 | $1.81 |
| Indicator | DOYU | MXCT |
|---|---|---|
| Relative Strength Index (RSI) | 26.71 | 69.59 |
| Support Level | N/A | $1.15 |
| Resistance Level | $4.90 | $1.54 |
| Average True Range (ATR) | 0.21 | 0.07 |
| MACD | -0.05 | 0.05 |
| Stochastic Oscillator | 4.00 | 85.69 |
DouYu International Holdings Ltd is a game-centric live streaming platform in China and a pioneer in the eSports value chain. The company aims to build an integrated game-centric ecosystem of livestreaming, video, voice, graphic content, and other interactive and community features. The company operates the platform both on mobile apps and PC portals, through which users can enjoy immersive and interactive games and entertainment livestreaming, access a wide array of video and graphic content, and participate in community events and discussions.
MaxCyte Inc is a life sciences company focused on advancing the discovery, development, and commercialization of next-generation cell therapies. It uses its proprietary cell engineering technology platform to support biotechnology and pharmaceutical customers in cell therapy, gene editing, immuno-oncology, and biologic development. It operates in one segment: cell engineering technology, which generates revenue mainly from product sales, licenses, research and clinical license fees, and program-related revenues as its SPL customers achieve development and regulatory milestones. Its platform, the ExPERT Platform, is based on Flow Electroporation technology designed to efficiently and safely modify human cells with high efficiency, low cytotoxicity, and scalability for clinical use.